The future of the weight loss market might not revolve around GLP-1 drugs.

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Expiry of Novo Nordisk’s UK patent for Saxenda seen as offering a ‘dry run’ for future generic versions of Ozempic ...

In a year and a half, Eli Lilly (NYSE: LLY) has roughly doubled in value. It is now the most valuable pharmaceutical company ...

Recent health news includes the FDA reconsidering its stance on compounded drugs, Australia's investment against bird flu, ...

This summary provides the latest updates in health news, including HIV cases from organ transplants in Brazil, Sanofi's ...

New estimates say that Medicare will spend tens of billions of dollars over nine years to cover weight-loss drugs.

New drugs from public and private companies are expected to saturate the obesity drug market. Novo Nordisk and Eli Lilly are currently dominating the weight loss drug market, but biopharmaceutical ...

Viking Therapeutics (NASDAQ: VKTX) and Summit Therapeutics (NASDAQ: SMMT) are both up-and-coming biotechs with no sales ...

In a report released on October 10, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Novo Nordisk (0QIU – Research ...